Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

CDK4/6 inhibitors (CDK4/6i) have improved survival of patients with estrogen receptor-positive (ER+) breast cancer. However, patients treated with CDK4/6i eventually develop drug resistance and progress. RB1 loss-of-function alterations confer acquired resistance to CDK4/6i, but the optimal therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chang-Ching, Chang, Tsung-Cheng, Wang, Yunguan, Guo, Lei, Gao, Yunpeng, Bikorimana, Emmanuel, Lemoff, Andrew, Fang, Yisheng V., Zhang, He, Zhang, Yanfeng, Ye, Dan, Soria-Bretones, Isabel, Servetto, Alberto, Lee, Kyung-min, Luo, Xuemei, Otto, Joseph J., Akamatsu, Hiroaki, Napolitano, Fabiana, Mani, Ram, Cescon, David W., Xu, Lin, Xie, Yang, Mendell, Joshua T., Hanker, Ariella B., Arteaga, Carlos L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371097/
https://www.ncbi.nlm.nih.gov/pubmed/37502925
http://dx.doi.org/10.21203/rs.3.rs-2966905/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371097/
https://www.ncbi.nlm.nih.gov/pubmed/37502925
http://dx.doi.org/10.21203/rs.3.rs-2966905/v1

Ejemplares similares